AB Science SA announced the issuance of a Canadian patent protecting the composition of matter of AB8939, including its use for treating acute myeloid leukemia $(AML.AU)$, with protection extending until 2036. This patent ensures comprehensive intellectual property coverage for AB8939 across critical markets, including the USA, Europe, China, Japan, South Korea, and more. Additionally, AB8939 has received orphan drug designation for AML from both the European Medicines Agency and the US FDA, providing market exclusivity post-approval. A secondary medical use patent application was filed to protect AB8939's use in treating AML with specific chromosomal abnormalities, potentially extending protection until 2044 for these patient sub-populations.